Cencora stock: Cencora schedules November 4 results for Cencora stock
Published on 10/20/2026 at 15:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and valuation
- Cencora scheduled fourth-quarter fiscal 2026 results for November 4, 2026.
- Third-quarter revenue reached USD 84.80 billion, up 5.10 percent year over year.
- Cencora stock costs EUR 305.50 at Lang & Schwarz on October 20, 2026 at 3:30 p.m. CEST, up 0.20 percent versus the Xetra close.
- The stock trades at a 25.26 price-to-earnings ratio with USD 65.5 billion in market capitalization.
Cencora Inc. has scheduled its fourth-quarter fiscal 2026 results for November 4, 2026, before trading opens in New York, according to Cencora. The company will hold its earnings call at 8:30 a.m. ET that day. Cencora stock was trading at EUR 305.50 at Lang & Schwarz on October 20, 2026 at 3:30 p.m. CEST, up 0.20 percent versus the Xetra close of October 19, 2026 at EUR 304.90.
Third-quarter revenue sets the scale
Cencora reported third-quarter 2026 revenue of USD 84.80 billion, up 5.10 percent from the third quarter of 2025. Net income reached USD 763.50 million, an 11.00 percent increase from the prior-year quarter, while earnings per share rose to USD 3.95 from USD 3.55, according to Simply Wall St.
Price position remains measured
The US-listed stock has a 52-week range of USD 244.82 to USD 377.54. The Lang & Schwarz price is 19.10 percent above the 52-week low and 19.08 percent below the high, using the USD range as the home-market comparison. The NYSE share price was last quoted at USD 343.38 on October 20, 2026 at 9:31 a.m. ET, with a market capitalization of USD 65.5 billion.
What matters before November 4?
Cencora trades at a price-to-earnings ratio of 25.26 and has a trailing dividend yield of 0.01 percent. The upcoming results will provide the next dated test of the revenue trend and the company's fiscal-year execution. Its distribution, commercialization, patient access, and pharmacy solutions serve pharmaceutical manufacturers, providers, and health systems in more than 50 countries.
Comparison with peers
Cencora: up 0.20 percent versus the Xetra close, price-to-earnings ratio 25.26, market capitalization USD 65.5 billion.
CVS Health: up 0.72 percent, price-to-earnings ratio 24.52, market capitalization USD 119.4 billion.
McKesson: up 0.92 percent, price-to-earnings ratio 27.04, market capitalization USD 118.9 billion.
Results date anchors the next move
The November 4 reporting date gives investors a fixed point for judging whether the 5.10 percent third-quarter revenue growth is carrying into the fourth quarter. The stock's 19.08 percent discount to its 52-week high leaves valuation and execution as separate considerations.
Cencora stock was trading at EUR 305.50 at Lang & Schwarz on October 20, 2026 at 3:30 p.m. CEST, up 0.20 percent versus the Xetra close of October 19, 2026 at EUR 304.90. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.
Cencora stock at a glance
- Company: Cencora, Inc.
- ISIN: US03073E1055
- Ticker: COR
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 20, 2026, 3:30 p.m. CEST): EUR 305.50
- Change versus Xetra close: plus 0.20 percent
- Xetra close (October 19, 2026): EUR 304.90
- Market capitalization: USD 65.5 billion (as of October 20, 2026)
- 52-week range: USD 244.82-377.54 (as of October 20, 2026)
- Sector / Industry: Health Care / Medical Equipment, Supplies and Distribution
Market context: Market report S&P 500.
